Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025
Atossa Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication for (Z)-endoxifen May 21, 2025
Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer May 21, 2025
Two Ph 2 trials of Samuraciclib + SERDs in HR+ve Advanced Breast Cancer demonstrate extended PFS in patients without TP53 mutations or without liver mets May 21, 2025
Enhertu followed by THP before surgery showed statistically significant pCR improvement high-risk HER2-positive early-stage breast cancer patients in DESTINY-Breast11 Ph 3 trial May 13, 2025
First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
CHMP recommends EU label update for Phesgo to allow administration outside of clinical settings May 6, 2025
Plans for Ph 3 1L vepdegestrant combo trial with atirmociclib and Ph 3 2L combination trial with a CDK4/6 inhibitor shelved May 6, 2025
Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced April 30, 2025
Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC April 30, 2025
FDA Clears IND Application for Ph 2 Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer April 30, 2025
Enhertu + pertuzumab in DESTINY-Breast09 Ph 3 trial demonstrated PFS improvement in vs THP as a 1L treatment for patients with HER2-positive metastatic breast cancer April 22, 2025
First Patient Dosed in Ph 2 Trial of HLX22 + T-Dxd in HER2-low, HR-positive Breast cancer patients April 22, 2025
Ph 2 study of Bria-IMT + CPI outperforms ADC drugs in HR+ metastatic breast cancer (MBC) patients April 22, 2025
Trodelvy + Keytruda Demonstrated PFS Improvement in Patients With Previously Untreated PD-L1+ Metastatic TNBC April 22, 2025
DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer April 15, 2025
Preliminary positive immune response data announced from Ph 3 clinical trial FLAMINGO-01 of GLSI-100 April 8, 2025
Enhertu approved in the EU for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy April 8, 2025
